首页> 外文OA文献 >PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

【2h】

PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

机译：pipac-ov3：多中心，开放标签，随机，双臂期III试验对顺铂和多柔比蛋白的无进展存活的影响，作为加压腹膜内气溶胶化疗（PIPAC）与铂患者单独的化学疗法抗性复发性上皮卵巢，输卵管或原发性腹膜癌

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

AI期刊论文写作 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Naoual Bakrin; Clemens Tempfer; Giovanni Scambia; Michele De Simone; Boris Gabriel; Eva-Maria Grischke; Beate Rau;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer [J] . ColomboN., KutarskaE., DimopoulosM., Journal of Clinical Oncology . 2012,第31期

机译：随机，开放标签的，III期研究，比较了铂难治性或耐药性复发性上皮性卵巢癌，原发性输卵管癌或原发性腹膜癌患者中帕特匹龙（EPO906）与聚乙二醇化脂质体阿霉素的比较
2. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer [J] . AghajanianC., BlankS.V., GoffB.A., Journal of Clinical Oncology . 2012,第17期

机译：海洋学：铂敏感性复发性上皮性卵巢癌，原发性腹膜癌或输卵管癌患者中，有或没有贝伐单抗的随机，双盲，安慰剂对照的Ⅲ期化疗试验
3. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023 [J] . Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, BMC Cancer . 2018,第1期

机译：在铂抗性上皮卵巢卵巢卵巢卵巢卵巢卵巢，输卵管或原发性腹膜癌症患者中使用Bevacizumab用于前线或铂敏感的抗蜂巢蛋白，或没有Bevacizumab的疗效和安全性评估患者的疗效和安全性卵巢癌：日本妇科肿瘤学群体研究JGOG3023的理由，设计和方法
4. PIPAC-OV3: A multicenter open-label randomized two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian fallopian tube or primary peritoneal cancer [O] . Naoual Bakrin, Clemens Tempfer, Giovanni Scambia, 2018

机译：PIPAC-OV3：一项多中心开放标签随机三臂III期临床试验对加压铂-腹膜内气雾剂化疗（PIPAC）与单独化疗的铂-铂类患者对顺铂和阿霉素的无进展生存期有影响耐药的复发性上皮性卵巢癌输卵管癌或原发性腹膜癌
5. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023 [O] . Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, 2018

机译：在铂抗性上皮卵巢卵巢卵巢卵巢卵巢卵巢，输卵管或原发性腹膜癌症患者中使用Bevacizumab用于前线或铂敏感的抗蜂巢蛋白，或没有Bevacizumab的疗效和安全性评估患者的疗效和安全性卵巢癌：日本妇科肿瘤学群体研究JGOG3023的理由，设计和方法

著录项

引文网络

相似文献

相关主题

期刊订阅